RespireRx Pharmaceuticals Inc (CE) (RSPI) Quote

Totally agree with you. Hope our good days will be sooner when we are back to trading.

Yep. Been that way for over a year. Company essentially notes that everyone is dependent on making this work. From debt and warrant holders to retail shareholders to stakeholders with equity in these candidates to all the insiders with preferred, phantom or other equity linked positions. Consternation around this EM approach and lack of presentation and communication certainly weighs on all.

Fingers crossed they are close to launching a transformation that sets these candidates and this company into the forefront for the benefit of all stakeholders including those who may need the potential medicine

I guess, once it gets out of Expert Market and starts trading, we will all have a boost! But when that will happen, who knows. I guess, other than waiting, not much we can do.

I need a lil boost myself. I’m getting all this partying out of the way.

No, still stalled, waiting for your boost so that we all can enjoy the smooth ride towards the successful long journey.

Your reply to George H on your other board you trash proves what a Loser you are as a human being.

Or should I say looser

Did the train, ship, and or plane leave without me?

I may have posted this before. RSPI, if it manages to re patent as previously discussed...

Modeling Suggests Combined-Drug Treatments for Disorders Impairing Synaptic Plasticity via Shared Signaling Pathways
Paul Smolen 1, Marcelo A Wood 2, Douglas A Baxter 1, John H Byrne 1


PMCID: PMC7878405 NIHMSID: NIHMS1646053 PMID: 33175283

Considerable recent data have supported the efficacy of ampakines. Two ampakines, CX-929 and CX-1846, have been shown to rescue deficits in LTP and spatial learning due to ageing (Lauterborn et al. 2016; Radin et al. 2016). CX-929 also rescues deficits in LTP and in fear conditioning in a mouse model of Angelman syndrome (Baudry et al. 2012). CX-691 has been reported to rescue a spatial learning deficit in a rat AD model (Mozafari et al. 2018). Treatment with CX-516 rescues deficits in LTP and in fear conditioning in another mouse model, of intellectual disability due to TM4SF2 deletion (Murru et al. 2017). The availability of tested TrkB agonists and ampakines, which cross the blood-brain barrier in rodents, strongly suggests testing of the efficacy of this drug combination in animal models of genetic disorders such as CLS that correlate with impaired histone acetylation, as we discuss previously, as well as in animal models of the other disorders above, such as Fragile X and AD. Recently 7,8-DHF and CX-929 have separately been reported to rescue deficient spatial learning in a mouse Fragile X model, with 7,8-DHF also rescuing deficient LTP (Seese et al. 2019).

Just another example of competitors pushing forward...

Let's hope Respire can make a push forward with their candidates as well.

Cardiff University spin-out Draig Therapeutics emerged from the shadows this morning with £107 million ($140 million) in funding to develop new therapies for neuropsychiatric disorders.

What is not mentioned is that though Respirerx’s competitor molecule CX-1632 was indeed put on hold, they have now several better new alternatives. Several.

Other drugs in the class have run into toxicity issues, including convulsions or neurotoxicity, which have scuppered development programmes such as Eli Lilly's mibampator and Servier/RespireRx' tulrampator.

One candidate that has stayed the course so far is Neurocrine Biosciences' osavampator, which is in phase 3 testing as an add-on therapy for patients with MDD who do not respond to standard antidepressants.

Along with MDD, AMPA-targeting drugs have also been proposed as potential treatments for other diseases, including Alzheimer's and cognitive impairment due to schizophrenia.


https://pharmaphorum.com/news/welsh-biotech-draig-emerges-140m-financing

$5.46 🤑if you're gonna go.... go big! imo

0.0015

Well, if what I suspect is true, that the ampakines are the keys to the doors also of somatic cells. Then a key ampakine could target somatic cells making them less insulin resistant and type 2 diabetes a disease of the past.

That’s quite a story there. Shows how quickly fortunes can evolve and flip..

This one has been hovering less than 2 million valuation for a year plus. Considering their progress with multiple candidates nearing clinicals for multiple indications.. would it surprise anyone if this too can reset valuations into 100s of million or more..

Jeeez, should I start looking for a mansion in the Hamptons or Atherton or both?

lol look at this one: Shares of Regencell Bioscience, a Hong Kong-based developer of traditional Chinese herbal treatments that it says can treat childhood ADHD and autism, more than tripled Monday. The stock soared more than 280% after a 38-for-1 stock split.
The company, which has no revenue, has jumped more than 59,000% in 2025 after gains continued Tuesday.

I think the shareholder letter and the commentary from the CFO some have posted this year essentially tells the story. They have many irons in the fire, many potential very promising and very lucrative candidates progressing towards human clinical trials and are strategically dealing to get the ball rolling on these many fronts...

IMO, there has been plenty of supposition about the intent of the EM. I am guessing the answer is a little more simple than complex but it is what it is at this point. They need to move forward with action and communication/presentation to put the black eye of the EM and the lack of leverage it created in the past.

The investment thesis going forward is simple. Get off the EM to a liquid market and normalize professional communication/presentation while updating on minor funding and our multiple grants status. This will alone achieve a new level for the company. From there, a more impactful update and progress on getting BP/venture funding to support clinical trials for KRM-ll-81 and CX-1739 will really launch this. Both candidates have massive potential to exponentially increase value. Land those strategic deals and then initiate clincals and with clinical success market valuations will really soar. GLTA.

Probably to just annoy us retail shareholders wondering wtf is going on.... Kinda surprised we have not see a single share sell at a penny or a dollar for comedic response.

But if the past is precedent, many have noted the illogical lot transaction size among other things as precursors of significant upticks in activity to come...

I wonder what the goal is for the sale of just one share?

Maybe this patent thing is the missing piece of the puzzle.

Of course. But the administration of their ampakines orally will provide RSPI twenty more years of patent life if I am right about this. But we will see, hopefully really soon.

I believe a new formulation or delivery mechanism attached to an old compound would be patentable but they would also need to start at preclinical phase which would not even be considered until their more mature and prominent assets generate funding and flexibility to explore. At some point it would be cool to see the old high impact ampakines and their potential be added to Respire's pipeline.. But their focus NOW needs to be get off the EM, improve presentation/communication, garner some funding and support capital, land as much grant funding as possible and get KRM-ll-81 and CX-1739 moving into clinicals so as to partner up with BP who can take the ball across the finish line... Nothing else matters.

Can a new patent be granted based on application not covered by the old patent?

Yes, a new patent can be granted for an invention that is not covered by a previously existing patent, even if the new invention builds upon the old one. The key is that the new invention must be considered novel and non-obvious compared to the prior art, including the earlier patent. This means the new invention must offer something significantly different and not readily apparent to someone skilled in the relevant field.

Oral administration is a game changer, IMO. Most of the studies the ampakine were injected.

My postings were more of an exploration into AI. But as you know, I am still fascinated by CX929 which appeared to be still controlled by RSPI and it was obvious to me that poor graduate student who couldn't publish his thesis was restrained by an NDA until 2026. I'm wondering if RSPI will be applying for a new patent based on the oral administration of most if not all their ampakines.

Looks to me the dam is about to burst..

Good luck to those still seeking a position.

My notes having Biovail dropping ampakines from their portfolio soon after they acquired them from Cortex, in which Cortex re-acquired them. SEC filings from Cortex say CX929 patent expired in 2022.

I have not found a single item to suggest RespireRX is pursuing high impact ampakines currently. I am curious to know if there is any new technology to justify exploring the viability of those old ampakines beset with significant side effects..

I think they are plenty busy with the low impact ampakines as well as the premier gabakine.

The "ampakine Family 5" patent likely refers to a group of patents or patent applications held by Cortex Pharmaceuticals, Inc. (now RespireRx Pharmaceuticals Inc. or RSPI) related to certain AMPAKINE compounds.
Biovail Laboratories International SRL had acquired rights to certain AMPAKINE compounds, including associated intellectual property, from Cortex Pharmaceuticals in March 2010. However, Cortex reacquired these compounds and rights from Biovail in March 2011.
The license agreement between Cortex and Biovail mentions restrictions on Biovail regarding the use of "Family 5 Patent Rights" and "Family 6 Patent Rights," implying that these patent families were owned by Cortex/RespireRx.
Specific expiration dates for patents within the "ampakine Family 5" are not explicitly stated in the search results. However, information about related AMPAKINE patents held by Cortex/RespireRx indicates the following:
A patent application specifically covering CX1739, a low-impact AMPAKINE, was projected to expire in 2028 if approved.
Other patents related to low-impact AMPAKINE compounds CX2007 and CX2076, issued in February 2012, were set to expire in August 2028.
RespireRx mentions a "Composition-of-Matter Patent" for CX1739 expiring in 2028, and a "Method-of-use patent" expiring in 2030.
The "last to expire patent" licensed from the University, relating to the reacquired compounds, expires in January 2025.
Based on this information, the most relevant patent expiration date among the search results that is likely associated with the "ampakine Family 5" and held by Cortex/RespireRx is 2030, which is the expiration date for a "Method-of-use patent" related to CX1739.
It is important to note that the specific expiration date for the "ampakine Family 5 patent" is not directly available, but the information provided gives an indication of the timeframe for patent expirations related to Cortex/RespireRx's AMPAKINE compounds.

Good job on that CX929 report Mexi. Now we just need the Canadians to get over the Cup loss and we could soar to unbelievable heights.

And "In the context of patent rights, "Family 5" likely refers to a grouping of patents and patent applications related to a single invention, which are referred to as a patent family. The "5" in "Family 5" would simply be a number assigned to this particular patent family, indicating its place within a larger system of patent families managed by a patent database or office.
Here's a breakdown of what a patent family means in relation to patent rights:
1. Single Invention, Multiple Territories:
A patent family represents a single invention that is protected in different countries or regions through a collection of patents and patent applications.
2. Common Priority Date:
All members of a patent family share a common "priority date," which is the date the initial patent application for the invention was filed.
3. Applications and Granted Patents:
Each family consists of applications and granted patents from the various countries where protection is sought.
4. Patent Family Size:
This refers to the number of applications or patents within a specific patent family.
5. Examples of Patent Families:
An example could be a US patent application and any subsequent patent applications filed in other countries (e.g., in Europe, Japan) to protect the same invention.
6. Importance of Patent Families:
Patent families help to organize and track related patent documents for a single invention.
They are particularly useful in patent analysis, preventing the "double counting" of inventions when evaluating patent activity across different countries.
In summary, "Family 5 Patent Rights" simply means that the patent rights in question belong to a specific patent family, which is a collection of patents and applications related to one invention, and this particular family is designated as "Family 5" within a specific database or system. "

OMG!!! AI is unbelievable! Just need to ask:

"Based on the information provided, BLS stands for Biovail Laboratories International SRL, a subsidiary of Biovail Corporation.
BLS entered into a License Agreement with Cortex Pharmaceuticals, Inc. (which later became RespireRx Pharmaceuticals Inc.). This agreement granted BLS an exclusive, worldwide, perpetual license related to Family 5 Patent Rights, which include reference to CX929.
This license was related to the acquisition of certain Ampakine compounds for the treatment of respiratory depression. "

LT - "BLS grants an exclusive, worldwide, perpetual license related to Family 5 Patent Rights, which include reference to CX929." This is all new to me. Any idea as to what it is talking about? Who is BLS? Google did not come up with a logical answer. And "Family 5?"

Agree, that is a good sign that maybe that phase 2 funded study is close to getting off the ground and initiating..

With the ampakines targeting SCI and ADHD
KRM-ll-81 for pain and epilepsy indications
and the OSA program...

Lots of irons in the fire, 5 major medical indications all approaching late preclinical into clinical trials. Many catalysts all likely needing funding sources, partners or collaborators to assist in supporting these endeavours... Once one gets going, the rest will be poised for progress as well. Entering a transformative time period..hopefully...

Thank you NeutrinoKid for the great update, I think we are moving in the right direction. GLTA

Does RespireRX have rights to CX929? AI answers:

Yes, RespireRx Pharmaceuticals Inc. holds intellectual property rights related to CX929, though the specific nature of those rights and their current status isn't explicitly detailed in the provided search results.
Here's a breakdown of what the information suggests:
RespireRx owns patents and patent applications or rights to certain chemical compounds claiming their structure and use in treating various disorders.
A "License Agreement" involving "Cortex" (presumably a predecessor or related entity to RespireRx) and BLS grants an exclusive, worldwide, perpetual license related to Family 5 Patent Rights, which include reference to CX929. This indicates RespireRx (or its predecessor) was involved in its development and held rights to it.
The specific context of CX929's use and development is mentioned in the License Agreement as being for specific conditions like "spinal cord injuries".
An article from ADVFN references CX929 in the context of RespireRx and potential oral administration, suggesting it is or was part of their research efforts.
However, the provided documents don't offer specifics on the current developmental status of CX929 or definitively state that RespireRx continues to actively pursue its development.
It's important to note:
RespireRx focuses on two main drug platforms: pharmaceutical cannabinoids (including dronabinol) and neuromodulators (AMPAkines and GABAkines).
While CX929 appears to be related to the neuromodulator platform (likely an AMPAkine), recent press releases and company overviews primarily highlight CX1739 as the lead AMPAkine.
Therefore, while RespireRx holds rights related to CX929, further investigation may be needed to determine its current significance within the company's development pipeline.

New website with up to date reference for the 1.8 million DoD award to Dr Milap Sandhu: Defense Technical Information Center

DOD Grant Award
Safety and Efficacy of Ampakines for Improvement of Bladder Function in Individuals with SCI
Funder: Congressionally Directed Medical Research Programs (CDMRP)
Award Number: HT9425-24-1-0497
-
Proposal Number: SC230095
Investigators
MILAP SANDHU - SHIRLEY RYAN ABILITYLAB
PI

https://dtic.dimensions.ai/details/grant/grant.14044909

Up to date information for CX1739 clinical trial on government website:

https://www.usaspending.gov/award/ASST_NON_HT94252410497_97DH

The other thing too is there is just not that many significant amount of shares floating around at this peanuts level less than 2 million valuation. Especially when the company announced several activities ongoing in their shareholder letter 5 months ago which logic would put them on the cusp of executing upon those catalysts and of course the company itself having several candidates poised to head into clinical trials and a company suggesting valuation in the 50+ million range or more...

Won't take much to see this race well into pennyland before any home run level news surfaces...

Yep. Lol. I don't know if some of those small share transactions less than a single buck are market entities tidying up their positions or true signals between expert investors... Several 911 trades again...

Hopefully they put in place some small funding to complete the filings and get off the EM and trading "normal" again. Some pipeline updates in regards to grant funding would be interesting as well. Obviously the big home run items would be transferring assets to EndeavourRx and getting large scale funding to support the neuromodulators heading into multiple clinical trials. The biggest one being exit tier 3 NIH-HEAL with an IND submission and phase 1 plan. This is speculated where BP could jump in but unknown. The epilepsy pathway is also very lucrative and whether they get grant funding to prep IND submission or have additional partnerships to get into epilepsy trials, that can be huge especially with robust preclinical efforts in their back pocket... Initiating the phase 2 DOD funded SCI trial could be significant and I would like to hear if CX1739 then becomes a candidate for ADHD and whether that is the indication for their grant funding application they mentioned..

So many potential small and large catalysts looming.... IMO, this story and significant valuation reset will occur over many upcoming months... But if this wants to shoot straight to .25 I won't complain... lol

Big money being made today HAHAHHA GLTA

0.25

0.001

0.0016

Trading by or before July 31st (my birthday) would be the best for my mom and I. 🌝

Pretty sure if you search thru old Cortex documentation the patent expired years ago on CX929 among other high impact ampakines…. They have been clear their focus had been on low impact only!

As discussed here and Neutrino could elaborate, a new technology would be needed to make past high impact ampakines viabke. Deploying new technology would require funding and restart preclinical phase.

Opening a zoo of the past makes ZERO sense when CX1739 is much more viable AND KRM-ll-81 has looked outstanding in preclinicals for high profile areas of pain and epilepsy..

Damn! AI sure is getting "thoughtful:"

There's no indication that RespireRx is "ignoring" CX929 ampakine. However, based on the information available, their focus has shifted to other ampakines, specifically CX717 and CX1739, for development in respiratory disorders and spinal cord injury.
Here's why this might be the case:
Focus on Lead Compounds: RespireRx emphasizes CX717 and CX1739 as their "lead clinical compounds," which have successfully completed Phase 1 safety trials and shown promise in Phase 2 proof-of-concept studies for treating opioid-induced respiratory depression and improving bladder function after spinal cord injury.
"Low Impact" Ampakines: RespireRx focuses on developing "Low Impact" ampakines, including CX717, CX1739, and CX1942, that avoid the seizure potential associated with "High Impact" ampakines. This suggests a strategic prioritization of specific ampakine profiles.
Specific Clinical Applications: Their focus is primarily on CNS-driven respiratory disorders, including opioid-induced respiratory depression, central sleep apnea, and disordered breathing from spinal cord injury.
CX929 Development Status: While CX929 has been studied in preclinical research and demonstrated positive effects in animal models for conditions like Huntington's disease, its development has been discontinued for certain indications, according to some reports. This discontinuation could be due to a variety of factors, such as resource allocation, strategic shifts, or regulatory decisions.
Financial Challenges: RespireRx has also faced financial challenges, which could impact its ability to pursue multiple drug development programs simultaneously.
In essence, RespireRx isn't ignoring CX929, but it appears to be concentrating its resources on the ampakines that have shown the most promise in clinical trials and align with its core focus on respiratory disorders and spinal cord injury.

LT CX929 is a high impact ampakine with an extraordinary clinical potential. AI explains it nicely:

Yes, CX929 is classified as a "high impact" ampakine.
Ampakines are a class of drugs that enhance the effects of the neurotransmitter glutamate at AMPA receptors in the brain.
They are being investigated as potential treatments for conditions involving cognitive impairments, such as Alzheimer's disease, schizophrenia, and Huntington's disease.
Ampakines are broadly categorized as either "high impact" or "low impact," depending on their effect on AMPA receptor activation.
CX929 falls into the high-impact category.
High-impact ampakines, like CX929, are thought to stabilize the open state of the AMPA receptor, influencing factors like agonist binding affinity and desensitization. This differentiates them from low-impact ampakines, which primarily accelerate channel opening with minimal impact on desensitization.
Preclinical studies on CX929 have shown promise in models of Huntington's disease, demonstrating improved cognitive function, reduced neuropathological changes, and enhanced motor performance.

I just do not believe Margolis claim of ignorance of CX929 when asked a while ago. But why the secrecy?

Hmmm.. Not that far fetched...

1 more day would be around .03 or 30 million market valuation
1 additional day would be around .50 or 500 million market valuation

The last presentation material from the company suggested around 50 million internal asset valuation. This is before any transformative license, partnership or sale dealings with major funding or BP entities..

IMO a reasonable projection soon would be for this company to get off the EM and acquire funding/resources to get multiple candidates moving in clinicals trials. At that point valuations somewhere in between those targets would be more than reasonable. Subesquently, success in phase 1/2 clinical trials could then quite possibly ecclipse high end range in the future... But until they hit GO, we will never know....

IMO it is the other way around...

That gabakine KRM-ll-81 is the key to unlocking further research into not only gabakines but all these historical and past ampakines which other than low impact CX-717 or CX-1739 I think no longer has anyone "owning" particular rights. KRM-ll-81 is the candidate that has been progressing... into tier 3 NIH HEAL, with possibly a SBIR grant for epilepsy IND enablement. This progression along BOTH the opioid/pain mitigation AND epilepsy paths are at a point that they require resources in terms of BOTH funding and capabilities. THIS is what we all are waiting to hear about and will then potentially unlock the funding and flexibility to pursue other candidates such as the high-impact ampakines which as you have illustrated in publications shows immense therapeutic potential, yet ALL high impact amapkines have not YET been able to overcome serious side effect profiles. New delivery mechanisms and combination technologies may be able to overcome this, but that requires FUNDING and flexibility.... Which we hope Respire can soon unlock.

My perspective only.. GLTA.

A couple more +1700% days and I'll be sitting pretty 😂

These fluctuations are something